Alliance Pharma (APH)

 

Latest News

Alliance Pharma building international sales, says Hardman

Hardman Research has issued a report noting that Alliance Pharma's Kelo-cote brand is building international sales. Hardm...

Hardman Research: Kelo-cote international sales

RNS Number: 7998T Alliance Pharma PLC 17 October 2017 Hardman Research: Kelo-cote building international sales Kelo-cote building international sales - Alliance Pharma's buy-and-build strategy to evolve into a profitable, cash generative, specialty pharma business is bearing fruit. Acquisition of the dermatology and woundcare products from Sinclair Pharma ha...

Alliance Pharma revenues and earnings rise

Alliance Pharma's revenues rose by 8% to 50.3m in the six months to the end of June. EBITDA increased by 3% to 13.6m an...

Interim Results

RNS Number: 5694Q Alliance Pharma PLC 13 September 2017 For immediate release 13 September 2017 ALLIANCE PHARMA PLC ("Alliance" or the "Company") Interim Results for the six months ended 30 June 2017 Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce its interim results for the six months ended 30 June ...

All News

DateHeadlineSource
17-10-17Alliance Pharma building international sales, says Hardman StockMarketWire
17-10-17Hardman Research: Kelo-cote international salesRNS
13-09-17Alliance Pharma revenues and earnings rise StockMarketWire
13-09-17Interim ResultsRNS
06-09-17Appointment of Joint Corporate BrokerRNS
01-08-17Notification of Interim ResultsRNS
31-07-17Broker Forecast - finnCap issues a broker note on Alliance Pharma PLCStockMarketWire
28-07-17Update on DiclectinRNS
25-07-17Changes to interests of a significant shareholderRNS
25-07-17Changes to interests of a significant shareholderRNS
18-07-17Half Year Trading UpdateRNS
13-07-1710 'crisis-proof' shares to buy and hold foreverMoney Observer
03-07-17Changes to interests of a significant shareholderRNS
26-06-17Changes to interests of a significant shareholderRNS
22-06-17Changes to interests of a significant shareholderRNS
21-06-17Application for block admissionRNS
19-06-17Changes to interests of a significant shareholderRNS
19-06-17Application for admissionRNS
14-06-17Application for admissionRNS
25-05-17Changes to interests of a significant shareholderRNS
25-05-17Result of AGMRNS
25-05-17Alliance Pharma cash flow remains strong StockMarketWire
25-05-17Hardman Res.: Transformed International BusinessRNS
25-05-17AGM StatementRNS
22-05-17Application for admissionRNS
18-05-17Fund manager's favourite small-cap pharma shares Interactive Investor
09-05-17Broker Forecast - finnCap issues a broker note on Alliance Pharma PLCStockMarketWire
08-05-17Application for admissionRNS
05-05-17Application for admissionRNS
05-05-17Changes to interests of a significant shareholderRNS
05-05-17Changes to interests of a significant shareholderRNS
04-05-17Changes to interests of a significant shareholderRNS
28-04-17Annual Report and AGM NoticeRNS
28-04-17Changes to interests of a significant shareholderRNS
24-04-17Changes to interests of a significant shareholderRNS
05-04-17Notification of Major Interest in SharesRNS
31-03-17Application for admissionRNS
29-03-17Full Year ResultsRNS
21-03-17Alliance Pharma settlement agreement with SinclairStockMarketWire
21-03-17Settlement Agreement with Sinclair Pharma plcRNS

RSS feeds

  • Editorial news feed for LSE:APH Editorial
  • Regulatory news feed for LSE:APH Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account